Challenger becomes substantial holder in Telix Pharmaceuticals

Challenger Limited, along with its associated entities, announced it became a substantial holder in Telix Pharmaceuticals Ltd (TLX) on September 3, 2025. The company's total voting power in Telix Pharmaceuticals stands at 5.00%, representing 16,927,111 ordinary fully paid securities.

The acquisition involved both on-market purchases and off-market transfers of ordinary fully paid securities. Between August 29 and September 3, 2025, Challenger entities engaged in multiple transactions. A "Sell - Transfer" transaction on August 29, 2025, involved a consideration of AU$3,476,143 for 238,092 securities. Numerous "Buy" transactions occurred on September 2 and 3, 2025, with individual considerations ranging from AU$22,316 to AU$782,313, acquiring between 1,572 and 54,897 securities per transaction.

Key registered holders of these securities include J. P. Morgan Nominees Australia Pty Limited with 3,369,554 shares, Citicorp Nominees Pty Limited holding 3,927,333 shares, HSBC Custody Nominees (Australia) Limited with 9,496,743 shares, BNP Paribas Nominees Pty Limited with 101,974 shares, and UBS Nominees Pty Limited holding 31,507 shares, all consisting of ordinary fully paid securities.